Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-Flutemetamol PET/MRI in Atherosclerosis
NCT03291093Phase 3Unknown
- Sponsor
- Maastricht University Medical Center+
- Start
- Feb 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of flutemetamol in atherosclerosis (3 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: 18F-Flutemetamol uptake in the carotids. Status: unknown.
02
Drugs
flutemetamol
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT03291093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03291093.